ArticleESMO open2023

First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors.

Y Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.